Grid Laser Photocoagulation for Macular Edema in Bilateral Juxtafoveal Telangiectasis

Park, Donald W.; Schatz, Howard; McDonald, H. Richard; Johnson, Robert N.

doi:10.1016/s0161-6420(97)30019-0

Cited by 82 publications

(43 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, numerous methods have been used for the treatment of type 2 IMT, including photocoagulation, 7 surgical removal of the subretinal neovascular membrane, 8 transpupillary thermotherapy, 9,10 PDT, 11,12 intravitreal triamcinolone acetonide administration, [13][14][15] and intravitreal bevacizumab administration. 6,[16][17][18][19][20][21] The results of these studies showed that bevacizumab was somewhat efficacious for the treatment of type 2 IMT.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia

Takayama

Ooto

Tamura

et al. 2010

Eye

View full text Add to dashboard Cite

Purpose To evaluate the effect of intravitreal bevacizumab injection for treating type 1 idiopathic macular telangiectasia (IMT). Methods Retrospective case series of five eyes of five male patients with type 1 IMT that were treated with 2-3 injections of intravitreal bevacizumab. Best-corrected visual acuity, foveal thickness obtained by optical coherence tomography, and fluorescein angiography (FA) were monitored over a period of up to 12 months. Results The average follow-up period was 17.0 months (range, 12-21 months). The mean logarithm of the minimal angle of resolution visual acuity was 0.295 at baseline and 0.254 (P ¼ 0.194) and 0.311 (P ¼ 0.461) at 3 and 12 months, respectively, after the initial injection. At 12 months, visual acuity had improved in one eye, remained stable in three eyes, and decreased in one eye. The mean foveal thickness was 479 lm at baseline; at 1 month after the therapy, marked reduction of macular oedema was seen only in one eye. The mean foveal thickness was 418 lm (P ¼ 0.287) and 473 lm (P ¼ 0.482) at 3 and 12 months after the initial injection, respectively. At 12 months, the foveal thickness had decreased by 4100 lm in one eye, but had increased by 4100 lm in two eyes. FA did not show a reduction in late leakage. Conclusions Treatment with intravitreal bevacizumab does not appear to improve visual acuity or retinal oedema in type 1 IMT.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia

Takayama

Ooto

Tamura

et al. 2010

Eye

View full text Add to dashboard Cite

show abstract

“…Laser treatment of the leakage area in type 2 IMT does not seem to improve visual acuity, but may even enhance vessel ectasia and promote intraretinal fibrosis [9]. During recent years and the advent of intravitreally applied anti-angiogenic drugs, new possibilities arose to stabilize vessel walls and to reduce fluid leakage and thereby oedema.…”

Section: Discussionmentioning

confidence: 99%

Bevacizumab in the treatment of idiopathic macular telangiectasia

Gamulescu¹,

Walter²,

Sachs³

et al. 2008

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…It appears to be most helpful in group 1 patients and not helpful in group 2 patients. While no large series of ALPC for IPFT have been reported, the largest series to date by Park et al [22] found no improvement or stabilization of vision with ALPC. Recently De Lahitte et al [23] reported that PDT was not beneficial for eyes with macular edema and IPFT without subretinal neovascularization.…”

Section: Discussionmentioning

confidence: 91%